ALAS1 and autoimmune pancreatitis: In the last 5 years, givosiran has transformed the landscape of AIP treatment via injectable mRNA silencing of the ALAS1 enzyme, in turn downregulating the production of potentially neurotoxic heme precursors ALA and PBG [32].